Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
Front Cardiovasc Med
This can aid in maintaining stable blood sugar levels and prolong feelings of fullness, controlling cravings and appetite
No herbal supplement can stimulate your bodys GLP-1 production in a way that leads to actual weight loss
In conclusion, the activation and promising application of GLP-1R offer broad possibilities for the future treatment of diabetes and related diseases
The main ingredient, berberine, can cause digestive side effects like diarrhoea, constipation, and an upset stomach